You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma

Article metrics

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma
Free

 

Online download statistics by month:

Online download statistics by month: October 2022 to September 2024

AbstractFullPdf
Oct 202259016
Nov 2022115031
Dec 2022114026
Jan 2023191035
Feb 2023161027
Mar 2023186023
Apr 2023162016
May 2023175015
Jun 2023177029
Jul 2023176030
Aug 2023353064
Sep 2023260050
Oct 2023244035
Nov 2023185032
Dec 2023177034
Jan 202410209
Feb 2024142019
Mar 2024206047
Apr 2024220037
May 2024234023
Jun 2024176045
Jul 2024236033
Aug 2024146021
Sep 20245802
Total42550699